maccura(SZ:300463)2022-11-23 06:58Group 1: Company Overview and Performance - Maccura achieved a revenue of 370,365.38 million yuan in 2020, representing a growth of 14.91% compared to the previous year [2] - The company reported a net profit of 79,542.03 million yuan, an increase of 51.43% year-on-year [2] - Basic earnings per share reached 1.4303 yuan, up by 50.65% from the previous year [2] Group 2: COVID-19 Product Development - Maccura developed COVID-19 testing products across three platforms: molecular diagnostics, chemiluminescence immunoassay, and rapid testing [2] - The molecular diagnostic platform's nucleic acid testing reagents received NMPA registration in March 2020, followed by CE certification and FDA EUA [2] - The company faced significant gaps in sales compared to other molecular diagnostic companies, but successfully streamlined its supply chain and achieved mass production within 2-3 months [2] Group 3: Market Strategy and Future Outlook - Maccura's strategy focuses on a "full product line, full industry chain" approach, which has allowed for rapid product development and market adaptation [3] - The company plans to expand its chemiluminescence immunoassay product line, with 51 registered reagents and a target of over 140 in the future [4] - The immunodiagnostics market, currently with a domestic market share of less than 30%, is expected to grow rapidly, driven by national policies supporting domestic manufacturers [4] Group 4: Stock Issuance Plans - Maccura received approval from the China Securities Regulatory Commission for a specific stock issuance on February 8, 2021, and is currently in the roadshow and investor interest assessment phase [6] - The company has not yet determined a specific issuance timeline, which will depend on market conditions and regulatory requirements [6]